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Abstract
The nasopharyngeal microbiome is a dynamic microbial interface of the aerodigestive tract, and a diagnostic window in the 
fight against respiratory infections and antimicrobial resistance. As its constituent bacteria, viruses and mycobacteria become 
better understood and sampling accuracy improves, diagnostics of the nasopharynx could guide more personalized care of 
infections of surrounding areas including the lungs, ears and sinuses. This review will summarize the current literature from a 
clinical perspective and highlight its growing importance in diagnostics and infectious disease management.
INTRODUCTION
As a microbiological niche, the nasopharynx (NP) demands 
an increased understanding of its dynamics, as the last ecolog-
ical reservoir bordering the relatively microbially scarce lower 
respiratory tract, sinuses and middle ear [1–4]. Infections of 
these three sites respectively represent the leading cause of 
childhood and neonatal mortality worldwide [5], the second 
most commonly antimicrobial- overprescribed [6], and the 
most common reason to seek medical attention for under- 5s 
in the USA [7]. In an era of antimicrobial resistance, transla-
tion of research from emerging molecular techniques and 
clinical stewardship measures will determine efficacious 
treatment [8, 9]. Whilst the oral flora are as logical a source 
of the microaspirations that seed lower airway disease as the 
NP, it seems to develop on a different taxonomic axis early in 
life [10–13]. Indeed, loss of oral/NP dissimilarity caused by, 
or associated with influx of oropharyngeal taxa into the NP 
precede respiratory tract infections (RTIs) [14]. As micro-
biological knowledge develops from a Kochian dichotomy of 
infection and health, the patient may in future be increasingly 
stratified within severity scales of disease or specific microbial 
profiles predictive of worse outcomes. The ‘Feverpain’ score 
stratifying patients into groups of relative risk of oropharyn-
geal streptococcal isolation based on symptomatology, and 
a classification model predicting Paediatric Intensive Care 
admission based on patient characteristics and isolated 
pathogens, are early examples of this [15, 16]. This review 
will describe the evolution of the healthy NP microbiome, its 
relevance to disease of the lower airways, sinuses and middle 
ear, and propose further areas of investigation and evidence 
synthesis.
Colonisation over lifespan
In the first year of life the genera Moraxella, Streptococcus, 
Corynebacterium, Staphylococcus, Haemophilus and 
Alloiococcus/Dolosigranulum predominate, with likely 
ancestry from maternal skin, vaginal and breast milk progeni-
tors [17, 18]. The NP rapidly develops as a distinct niche 
from the oral cavity with a seemingly protective increase 
in diversity [19]. Serial sampling of the NP in relatively 
healthy (>3 RTIs per year) children >1 yr with a showed 
early overgrowth with streptococcal spp., supplemented by 
Corynebacterium and Dolosigranulum with later colonization 
with Moraxella after 2–3 months. These roles were reversed 
in those with increased RTI frequency where Moraxella 
dominated earlier and Corynebacterium and Dolosigranulum 
remained less established [20]. Similarly, pre- term NPs are 
associated with within- group heterogeneity compared to 
the full term, a potential instability mimicking that seen in 
ensuing Rhinovirus infection, notably decreased abundance 
of Corynebacterium and Alloiococcus [21]. At 18 months, 
Enhydrobacter replaces streptococcal spp. when describing 
the six predominating operational taxonomic units (OTUs) 
(defined as being present in over 50% of nasopharyngeal 
samples). Indeed Proteobacteria, along with Fusobacteria 
and Cyanobacteria, achieve a seasonal abundance in autumn/
winter that is lost by spring, which invites transient growth of 
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study, the overall microbial diversity of the nasopharynx did 
not significantly fluctuate between autumn, winter and spring 
[22]. Over childhood and into adulthood there develops a 
richness in NP taxa, accompanied by increased evenness [23] 
and diversity in neighbouring oropharyngeal flora, relative to 
adults and elderly presenting to the emergency department 
with pneumonia [24]. Within adults aged 50–80, there is a 
greater absolute number of pathogens extracted by swabs in 
men compared to women [25]. The topographical dissimi-
larity between the anterior nares and oropharynx seen in the 
middle aged is lost within the elderly population; such tran-
sitions in microbiome may precipitate or avail of increased 
susceptibility to disease in this population [26]. This mimics 
the loss of variance between the oral and nasopharyngeal 
diversity associated with predisposition to disease early in 
life [27]. However larger more longitudinal studies within the 
adult population are required to describe the vectors therein.
Environmental/aetiological factors influencing NP 
microbiome composition
The evolution of the healthy microbiome cannot be reduced 
to a gradual collection of key OTUs upon the epithelial 
seabed. Many other aetiological and iatrogenic factors affect 
its development. Breastfeeding showed a significant change 
in the 6 week microbiome compared with formula feeding, 
notably with increased presence and abundance of classi-
cally commensal Dolosigranulum and Corynebacterium [28]. 
Significant decrease in abundance of these two potentially 
keystone species is noticed in infants who had antibiotic use 
in the preceding 4 weeks before sampling [29]. Short- term 
corticosteroid inhalation was not found to significantly alter 
the nasopharyngeal microbiome, but longer- term studies are 
needed [30]. Smoking appears to have a positive impact on the 
raw incidence of known pathogenic genera, and suppressing 
key ‘interfering’ species, but many of these studies have been 
underpowered [31, 32]. Lower socioeconomic indicators 
correlate with increased prevalence of M. catarrhalis, S. aureus 
and antibiotic- resistant S. pneumoniae, and epidemiological 
factors such as older siblings, daycare attendance and rural 
occupancy exerted a positive pressure toward pathogen 
carriage [33, 34]. These studies were conducted with tradi-
tional culture, not quantitative and sensitive molecular 
techniques however, therefore potential for false negatives is 
high. Pig farming has a positive and unsurprising effect on 
nasopharyngeal diversity indicating that the external environ-
ment has a key role in determining the final NP microbiome 
composition [35]. In line with similar findings in the gingivae 
and dental plaques, bacterial biofilms have been established 
as a mode of survival on the adenoidal surface [36–38]. As 
a sustaining and protective extracellular resin, biofilm is 
emerging as a necessary in vivo concept with relevance to 
therapy and microbial synergy in understanding the micro-
biome in health [39]. Whether or not biofilms are a driver 
of respiratory disease is yet to be established [40]. This rise 
in incidence of pathobionts is also noticed with lower lean 
body mass to fat ratios in men and higher waist- to- hip ratios 
in females, both considered markers of fertility and immune 
competence [41]. Immunomodulatory effects are noticed in 
raised serum Vitamin D levels, which reduce self- reported 
symptoms of the upper RTI: ears, sinuses, malaise and use 
of antibiotics in the immunosuppressed, and Vitamin D also 
augments dendrocyte maturation and matriculation against 
pneumococcal peptidoglycan in vitro [42, 43]. The asthmatic 
core microbiome identified in a study with mean age 11 
years mimicked the previously described core microbiome 
at 18 months, but without Enhydrobacter and with Morax-
ella, Haemophilus and Streptococcus being observed in 95% 
of samples, the same trio previously noticed in Rhinovirus 
susceptible infants [44, 45]. There may be further unknown 
pharmacological, meteorological or behavioral pressures as 
yet unstudied.
Pathogens, pathobionts and commensals: changing 
roles for the NP microbiome
The diverse microbial landscape is further involved by the rela-
tive pathogenicity of organisms, with microbes traversing the 
commensal- pathogen continuum depending on circumstance 
and coinfection. Pneumococcus for instance, commonly 
considered the main causative agent of pneumonia, may be 
considered a member of the healthy nasopharynx [46], and 
conversely species considered normal commensals may be 
implicated in severe disease of the immunocompromised 
[47]. The introduction of the pneumococcal vaccine has 
reduced disease burden, but has led to serotype replacement 
of S. pneumonia, and immediate epidemiological shifts in 
carriage of non- typable Haemophilus influenzae [48, 49]. 
Similarly Moraxella spp., long considered a benign human 
symbiont, has been implicated in a consistent percentage 
of middle ear and sinus infections, and are an important 
cause of exacerbations of chronic obstructive pulmonary 
disease [50]. Colonization rates, determined by culture, of 
S. pneumoniae, S. aureus and M. catarrhalis were significantly 
higher in patients with variant types of mannose- binding 
lectin, Toll- like receptor 2 (TLR2) and TLR4, respectively, 
receptors upregulating the innate immune system derived 
from polymorphic alleles, suggesting a genetic basis for 
variable colonization [51]. The underlying bacteria–bacteria 
and virus–bacteria and immune–bacterial interactions are 
complex, and the exact link between competition, overgrowth 
and disease manifestation requires considerable future study 
[52, 53].
The virome and mycobacteriome in health
The NP virome is a common cause of upper respiratory illness. 
Metagenomic analysis of NP swabs yielded a mean 86 viral 
sequences per sample in children under 3 with unexplained 
fever, compared with 56 from health controls, as well as greater 
richness and diversity [54]. This greater yield was a contradic-
tion to previous purely PCR- based studies with little or no 
viral load detected in normal controls, controls which though 
significantly predict health, suggest a benign carriage akin to 
the commensal bacteriome [55, 56]. This high sensitivity of 
viral presence in under 3s via next- generation sequencing 
was replicated in a second case- controlled study, where 71.2 
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% ‘healthy’ NPs contained viral nucleic acid compared with 
94.4% of children with recurrent otitis media, with Polyoma-
virus, Bocavirus and Rhinovirus prevailing in health, the latter 
with incidence as high as 42.4% [57]. The Anelloviridae family 
however has been identified as the most prevalent in febrile 
children on metagenomic analysis [58]. Anthropologically, 
the presence of various Rhinovirus strains occur between 
aboriginal and non- aboriginal children at different rates, 
and are associated with Moraxella and H. influenzae within 
both populations, pathogens deemed responsible for otitis 
media [59, 60]. Haemophilus is further overrepresented in 
infants hospitalized with Respiratory Syncytial Virus (RSV) 
and drives response of mucosal cytokine CXCL8, while clear-
ance of RSV is delayed in infants with a Haemophilus domi-
nated NP microbiome [61, 62]. More recently, comparison 
of COVID-19 specimen collections under strict conditions 
favoured the NP as more likely to yield the virus than the 
oropharynx [63]. NP dysbiosis has also been associated with 
disease severity in Mycoplasma pneumoniae pneumonia 
compared with healthy controls [64]. Fungal disease is not 
normally implicated in the NP being unique to the paranasal 
sinuses [65].
Lung, sinus and gastrointestinal relationships to 
the NP microbiome
The microbiome of the lung has been described as ecologically 
similar to the NP. The relatively abundant phylae Bacteroides, 
Firmicutes and Proteobacteria, however, have been a subject of 
doubt, whether selectively repatriated from the upper respira-
tory tract, or selectively contaminated whilst sampling the 
oropharynx [66]. Sterile dissection of healthy smokers' lungs 
have confirmed this microbiome, distinct from the oral cavity 
or nasopharynx, and more robust models of sterile sampling 
and controls for lavage contamination and oropharyngeal 
sampling confirm specifically lung- enriched organisms 
[67, 68]. As well as a source of emissary pathogens to the 
lungs, the NP microbiome may offer a diagnostic window to 
the rest of the respiratory tract. Furthermore, prevalence of 
keystone species at this level may gate downstream transmis-
sion of pathogens by colonization resistance [69]. Asthma 
control tests, an indication of how well asthma has been 
controlled over the preceding 4 weeks, was significantly lower 
in subjects with no viruses detected on NP swabbing than 
those with detected viruses [70]. NP swabs clear of viruses 
demonstrated lower NP microbiota compositions vary not 
only with RTIs but gastrointestinal infections also, inferring 
synergy of the wider metabiome [71]. Acute rhinosinusitis 
(RSS) is marked by symptoms of nasal congestion and nasal 
discharge, or facial pain or anosmia [72]. Prior history of RSS 
was associated with a significant depletion of NP taxa from 
over 100 genera, with only the species Moraxella nonliquefa-
ciens demonstrating an increase in relative abundance [73]. 
Longitudinal studies through acute disease are required 
to describe dynamics more fully, but such statistically 
outlying OTUs, if detected on a consistent basis, may serve 
as biomarkers to predict or confirm disease. The NP acting 
as a reservoir for sinus infection model has been supported 
by a conventional culture study linking successfully detected 
pathogens at the osteomeatal complex in the mid- nasal 
cavity to a >90% coincidence in the NP [74]. More recent 
gene sequencing of microbiota from functional endoscopic 
sinus surgery patients found a microbiome similar to the 
anterior nares (AN), which became transiently similar to the 
NP at the time of operation, and then regressed to its original 
niche equilibrium after 6 weeks [75]. Dissimilarity between 
the almost isolated sphenoid sinus and the rest of the nose, 
manifests as increased detection rates of resistant commensals 
and anaerobes, however this study was underpowered and 
used culture techniques [76]. Multidisciplinary collaboration 
between clinicians and scientists along both respiratory and 
age continua will be required to further characterize their 
dynamics and provide clinical application.
Otitis media
The otitis media (OM) culprit pathobiont triad in the conven-
tional culture era were Haemophilus influenzae, Moraxella 
catarrhalis and Streptococcus pneumoniae, joined by Alloio-
coccus otiditis with PCR- based diagnostics, a pathogen so 
ubiquitous in the middle ear of previously antibiotic treated 
children as to raise suspicion of a facultative or saphrotrophic 
nature [77–79]. Alloiococcus, however, was found to be absent 
in the NP and predominating in cultures of middle ear fluid 
from perforated eardrums, suggesting its external ear origin 
[80–82]. The NP of children with OM, in whom it is rela-
tively prevalent, is implicated with the above three classically 
cultured pathogens [83]. Quantitative- PCR detected the 
prevalence of Haemophilus in OM approaching the 90% NP 
detection rate of the same pathogen, a correlation not shared 
by Moraxella and Streptococcus spp. [84]. Next- generation 
sequencing of the NP in recurrent acute OM patients showed 
increased abundance of Corynebacterium and Dolosigranulum 
in healthy controls, with a lesser role played by Moraxella. 
Dolosigranulum pigrum is closely related to Alloiococcus, and 
Corynebacterium is from the same family as the otopathogen 
Turicella, suggesting possible colonization resistance for at 
least these genera [85]. These two, however, are very success-
fully inhibited by β-lactam antibiotics, therefore measures 
to employ more judicious use of these agents would be 
welcomed [86–88]. A more amenable relationship between 
bacteria–virus co- offenders S. pneumoniae and Rhinovirus, 
and Moraxella and Adenovirus, is evident in their statistically 
correlated abundance in recurrent acute OM in one cross- 
sectional study. With a 25% co- occurrence of most abundant 
viruses Rhinovirus and Bocavirus within its healthy controls, 
this may be a baseline virome not displaying obligate patho-
genicity [89]. This opportunism spotlights a realm of known 
unknowns within aetiological factors capable of tipping this 
dormant microbiome into disease.
NP profiling and health
NP microbiota in children under 1 year with bronchiolitis 
dominated by Haemophilus and with low levels of CCL5, a 
β-chemokine, has linear positive correlation with hospital stay 
when a Moraxella- dominated profile is used as a control, and 
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that this trend was maintained when an AN swab was utilized. 
The AN is a not entirely comparable microbiological niche, 
where staphylococcal species represent 40 % total abundance 
compared to >5% in the NP [90–92]. Further profiling of the 
AN in a similar cohort showed the lowest proportion of patients 
developing severe bronchiolitis in the Moraxella- dominant 
group (14%) compared with Staphylococcus- dominated 
(47%). It is intriguing to speculate whether a similar trend 
could be found further back in the nasal cavity [93]? Bron-
chiolitis treatment escalation to mechanical ventilation was 
predicted specifically and sensitively by a select panel of 25 
metabolites, which in turn mirrored relative abundance of 
S. pneumoniae, thus promoting the metabolome as a bacterial 
marker [94]. A multivariate analysis of associations of the NP 
microbiome within patients showed positive association with 
S. pneumoniae and H. influenzae and M. catarrhalis, siblings, 
daycare use, rhinoviruses and enteroviruses. There was a 
corresponding negative association with S. aureus carriage, 
recent antimicrobials, and the 7- valent pneumococcal vaccine 
[95]. A similar profiling of NP microbiota and patient charac-
teristics established a ‘high’ degree of accuracy in predicting 
lower RTI and length of hospital stay from a 29- point score 
derived of the most indicative bacteria and viruses and patient 
factors. Thus antimicrobials are strongly indicated to prevent 
severe pneumonia, but with an underlying need for a strati-
fied approach. It found relative scarcity of Dolosigranulum 
and Corynebacterium spp. and to a slightly lesser extent 
Moraxella spp. in those escalated to intensive care compared 
with controls [96]. Characterization of the NP microbiomes’ 
ability to prevent or accelerate viral respiratory infection is 
frustrated by the heterogeneity of study methods, lack of 
data from adult populations and poor taxonomic resolution 
[97]. Furthermore, the immune response against viruses is 
in turn modulated by gut microbiota, susceptible to the same 
deleterious effects from antimicrobials [98]. Nevertheless, in 
the light of the coronavirus pandemic of 2020, a theoretical 
underpinning for protective NP profiles could not be more 
welcome.
The nasopharyngeal microbiome and antimicrobial 
resistance
Pressure on the NP microbiome by antibiotics could yield 
less protective profiles. Alpha diversity decreases linearly 
with antibiotic doses, whilst significantly increased relative 
abundance of Haemophilus is found in children aged 1–6 
who had received antibiotics in the preceding 3 months 
compared to those who had not [99]. Thus, even before 
resistant pathogens are detected, disease susceptible states 
can persist following antibiotic use. S. pneumoniae resistant 
to Amoxicillin, Erythromycin and Co- Trimoxazole persist 
at stable rates throughout the first year of life within the 
South African population despite pneumoccocal vaccina-
tion at 6 weeks, and despite only 4% of HIV- exposed infants 
receiving the recommended Co- trimoxazole prophylaxis 
[100, 101]. Whole- genome sequencing (WGS) is more 
sensitive for detection of potential pathogens in patients 
with recent antimicrobial use compared to conventional 
culture [102]. The advent of WGS has shown great promise 
for decision- making around patient isolation, with the use 
of rapid WGS to classify skin and gut commensals in one 
hospital leading to a net saving of €200,000in blocked beds 
over 6 months despite high sequencing costs [103]. Such 
de- escalation of care would be well adapted to the high 
antimicrobial use seen in the upper respiratory tract.
Sampling the NP
Accurate sampling of the NP tract remains a challenge 
to establishing a baseline NP microbiome. Despite the 
technique of nasopharyngeal swabbing and washes being 
standardized by the World Health Organization (WHO), 
considerable heterogeneity had been noted within clinical 
practice during the COVID-19 pandemic [104–107]. The 
nasopharynx is defined as a subcomponent of the upper 
throat or posterior nasal cavity. However during a recent 
systematic review of the scientific literature using risk- of- 
bias assessments and quality checklists, the anterior nares 
and posterior oropharyngeal wall have been found to be 
included within the term ‘nasopharynx’ [108, 109]. Accu-
racy is important: alpha diversity indices for brushings of 
the inferior turbinate was increased vs. washings of the 
whole nasal cavity; whether this was due to a richer sampled 
environment or removal of pathogens with a greater range 
of mucosal adhesion is difficult to assess [110]. Biogeog-
raphy of the sphenoethmoidal recess and middle meatus 
displayed similar ecosystems likely related to their ciliated 
pseudostratified columnar epithelium, and dissimilar to 
the nonkeratinized, squamous epithelial inhabitants of the 
AN [111, 112]. Such studies rely on specialist equipment 
and expertise to accurately sample different sites. In some 
studies, nasal washings have yielded a higher colonization 
rate than swabbing of the posterior NP, but with implica-
tions of discomfort and suitability for an older paediatric/
adolescent population [113–115]. Interestingly, once at the 
nasopharynx, completing the mandatory rotations did not 
have a major effect upon discomfiture [116]. Contamina-
tion of sampling by sites encountered en passant has to be 
a key consideration when moving beyond single pathogen 
carriage to quantifying microbial communities. Otolaryn-
gological expertise has been relied on to specifically sample 
the nasopharynx in isolation [117, 118]. Innovation for 
this problem may include a ‘punch mechanism’ swab or 
a retractable guard for the swab head to sample the back 
of the nasal cavity only. When removed, the samples may 
themselves display further interactions: broth enrichment 
has been shown to favour overgrowth of phyla that would 
be disadvantaged in vivo at the expense of pathogens, and 
storage conditions affect microbial profiles as detected 
by 16S rRNA gene sequencing [119, 120]. The limita-
tions of conventional culture persist from the laboratory 
to the clinic, with pathogen detection on sinus culture 
being unable to identify patients who would develop 
RSS- consistent radiological changes [121]. For pathogens 
enmeshed within biofilm, fluorescent in situ hybridization 
(FISH) had around twice the sensitivity of culture, invoking 
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deeper sampling techniques for these landscapes [122]. 
Similar challenges exist with viruses: amplification of the 
specific fragment of the genome of common respiratory 
viruses via PCR has a sensitivity as low as 53 % with enzyme 
linked immunosorbent assay, and 71% by PCR [123, 124].
Conclusion and future steps
The NP is an emerging as an arena in the fight against pneu-
monia and upper RTIs, and a reservoir evolving specific 
resistance patterns [125]. Encouraging developments have 
included the increase in diversity and stability of the NP 
microbiome since introduction of 7- and 13- valent pneumo-
coccal vaccines, preceding a reduction in the incidence of 
OM [126]. Ingestion of probiotic yoghurt shows a significant 
decrease in the prevalence of Gram- positive pathobionts in 
humans, whilst probiotic application of Corynebacterium 
strains has been shown to replace S. aureus in humans and 
reduce viral load, lung changes and weight loss during RSV 
infection in mice [127–129]. Moving from marksmanship of 
culprit pathogens to shotgun sequencing of a patients’ entire 
microbiota at time of acute illness will guide increasingly 
accurate and judicious treatment of NP- derived infections. 
WGS is already being used to trace epidemiological links 
within outbreaks such as COVID-19 [130, 131]. For more 
common infections, ‘syndromic panels’ to detect carriage of 
a wide array of microbiota direct from samples have been 
available for the last decade [132]. Initial data on non- rapid 
WGS, defining infection as patients with exponentially 
prevalent overgrowth of key pathogens, suggests it can 
yield greater sensitivity, if not specificity, than conventional 
culture. Marriage of these technologies could inform front- 
of- house clinical decisions for more common infections in 
future. The generation of patient- specific microbial profiles 
may be able to distinguish health from disease, resistance 
patterns and specific dysbioses through emerging point- 
of- care whole- genome sequencing and clinical prediction 
tools [133, 134]. Such profiles available to clinicians may aid 
in decision making around ventilation, detection of disease 
in other body systems, and even transplantation of new 
microbiomes [135–137].
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